Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Cytek Biosciences Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned, representing 0% of the class as reported in the amendment.
The filing notes an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or business divisions to report separately; Vanguard states it no longer is deemed to have beneficial ownership of securities held by those entities.
Cytek Biosciences, Inc. director and chief technology officer Yan Ming reported a bona fide gift of 1,176,000 shares of Common Stock. The transfer carried a reported price of $0.00 per share, reflecting that it was a non-cash gift, not a market sale. After this disposition, Ming’s direct holdings are reported at 4,915,933 Common Stock shares, indicating he retains a substantial ownership position in the company.
Cytek Biosciences director Richard Chin exercised restricted stock units into common shares. On this date, 6,107 Restricted Stock Units converted into 6,107 shares of common stock at no exercise price. After the transaction, he directly holds 16,285 shares of common stock and 57,004 Restricted Stock Units.
The footnotes explain that each RSU represents a contingent right to one share of common stock and describe a multi‑date vesting schedule, with portions of the award vesting on specified dates in August, November, March, and May until fully vested.
Cytek Biosciences, Inc. Chief Legal Officer Valerie Barnett reported equity compensation and vesting activity. She received a stock option grant for 120,114 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years. She was also granted 226,453 restricted stock units (RSUs) that vest over four years on specified May, August, November, and March dates. On the same date, several earlier RSU awards vested, converting a total of 29,722 RSUs into common shares. Of these, 11,748 shares were withheld at $4.23 per share to cover tax obligations, and the remainder increased her directly held common stock to 134,436 shares. These are compensation-related grants, exercises, and tax withholdings rather than open‑market purchases or sales.
Cytek Biosciences SVP Philippe Busque reported equity compensation and vesting activity. On March 10, 2026 he received an employee stock option for 70,665 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years. He was also granted 133,226 restricted stock units, each representing one share of common stock, scheduled to vest over four years under specified annual dates.
On the same date, several existing RSU awards vested, leading to the issuance of 9,828 shares of common stock through derivative exercises, while 3,043 shares were withheld by the company at $4.23 per share to cover tax obligations. Following these transactions, Busque directly held 35,687 shares of common stock.
Cytek Biosciences President and CEO Wenbin Jiang reported several equity compensation transactions. He was granted an employee stock option for 485,545 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years, and a new award of 915,407 restricted stock units (RSUs) that also vest over four years on specified May, August, November, and March dates.
On the same date, previously granted RSUs vested and were converted into common stock in tranches of 15,708, 29,467, and 38,669 shares. To satisfy tax withholding obligations from these vestings, 3,825, 7,747, and 9,416 shares of common stock were surrendered back to the company at $4.23 per share. After these transactions, Jiang directly owned 5,422,683 shares of common stock.
Cytek Biosciences Chief Financial Officer William D. McCombe reported new equity awards and routine vesting-related activity. He received an employee stock option for 136,205 shares of common stock at an exercise price of $4.23 per share, expiring on March 9, 2036, which vests monthly over four years. He was also granted 256,790 restricted stock units, scheduled to vest over four years under detailed annual vesting schedules. On the same date, 6,320 and 17,401 RSUs converted into common shares, and a total of 9,748 common shares were surrendered at $4.23 per share to cover tax withholding obligations. Following these transactions, he directly holds 94,687 shares of common stock.
Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported several equity compensation transactions. On March 10, 2026, Ming received an employee stock option for 120,688 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years. He also received 227,535 Restricted Stock Units (RSUs), which vest over four years in specified tranches each May 18, August 18, November 18, and March 10 according to the award schedules.
Ming exercised previously granted RSUs covering a total of 25,400 shares of common stock. Of the resulting shares, 7,731 shares were withheld and surrendered to Cytek Biosciences at $4.23 per share to satisfy tax withholding obligations, and the remaining shares increased his direct common stock holdings. After these transactions, Ming directly owned 6,091,933 shares of common stock.
Cytek Biosciences director Michael Holder reported the vesting and exercise of restricted stock units into common shares as part of his equity compensation. On March 10, 2026, 2,908 RSUs converted into 2,908 shares of common stock at no cash cost, lifting his directly held common stock to 15,267 shares after the transaction.
Cytek Biosciences reports 2025 results and outlines its strategy as a leading cell analysis solutions provider built around its patented Full Spectrum Profiling (FSP) flow cytometry technology. The company sells Aurora, Northern Lights, Aurora Evo and Aurora CS instruments, reagents, software and services to pharma, biotech, CROs and academic labs worldwide.
Revenue was $201.5 million in 2025, up slightly from $200.5 million in 2024 and $193.0 million in 2023, while the net loss widened to $66.5 million from $6.0 million in 2024 and $12.1 million in 2023. Cash, cash equivalents, restricted cash and short-term investments totaled $261.5 million as of December 31, 2025.
The filing highlights new products such as the Aurora Evo system, Enhanced Small Particle detection, the Muse Micro analyzer and expansion of manufacturing in China and Singapore. Cytek emphasizes recurring consumables, software ecosystems like Cytek Cloud, clinical applications, global scale and an intellectual property portfolio protecting its FSP platform.